HC Wainwright & Co. Downgrades Genmab to Neutral
HC Wainwright & Co. analyst Raghuram Selvaraju downgrades Genmab (NASDAQ:GMAB) from Buy to Neutral.
Stocks That Hit 52-Week Highs On Friday
Before 10 a.m. ET on Friday, 52 companies hit new 52-week highs.
SVB Leerink Maintains Market Perform on Genmab, Raises Price Target to $42
SVB Leerink analyst Jonathan Chang maintains Genmab (NASDAQ:GMAB) with a Market Perform and raises the price target from $37 to $42.
The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 5)
Stocks That Hit 52-Week Highs On Thursday
On Thursday morning, 159 companies achieved new highs for the year.
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 4)
Stocks That Hit 52-Week Highs On Wednesday
Before 10 a.m. ET Wednesday, 138 stocks hit new 52-week highs.
The Daily Biotech Pulse: Pfizer’s Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 3)
Stocks That Hit 52-Week Highs On Tuesday
During Tuesday's morning trading, 101 companies set new 52-week highs.
Stocks That Hit 52-Week Highs On Friday
On Friday morning, 154 companies achieved new highs for the year.